Novo Nordisk A/S Common Stock (NVO)

Trump's vow to slash weight-loss drug prices sent Hims & Hers tumbling. These ETFs are facing new pressure.

Novo Nordisk offers cheap stock with strong moat and long-term growth tailwinds. Trump's drug price cut suggestion caused short-term volatility but...

Shares of Danish pharmaceutical giant Novo Nordisk are trading lower Friday morning, continuing an after-hours slide that began Thursday.

Novo Nordisk and Eli Lilly stocks slumped Friday after President Donald Trump said he would cut the price of obesity drugs.

Greg Miley stated that he will join Novo Nordisk next month as the company’s senior vice president of corporate affairs.

The financial markets experienced a turbulent Friday, October 17, 2025, as the Dow Jones Industrial Average faced a downturn driven by a resurgence of fears within the banking sector. Concurrently, pharmaceutical giants Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) saw their shares plummet following a new round of

Eli Lilly shares are trading lower Friday, among other GLP-1 drug manufacturers, following Trump's comments that fat-loss drugs will be a lot lower in price.

Trump's promise to cut cost of Novo Nordisk A/S drug Ozempic from $1,300 to $150 shakes GLP-1 gold rush, with potential impact on Eli Lilly and Pfizer.

While Dow Jones futures were down by 0.13% at the time of writing, the S&P 500 futures declined 0.41%.

These stocks have climbed in the triple digits over the past few years.

Novo Nordisk is also continuing discussions with the administration under the Most Favored Nation policy aimed at linking U.S. drug costs to global benchmarks.

Shares of Eli Lilly and Novo Nordisk move lower in Thursday's after-hours session after President Trump indicated weight-loss drugs are going to go down in price.

Hims & Hers (HIMS) has seen surprising success, up 150% YTD, driven by their new menopause specialty and refocusing on healthcare.

Find out if the deal Omeros announced is enough of a reason to buy this stock.

The rally followed H.C. Wainwright’s price target hike to $20 on the back of a $2.1 billion licensing deal with Novo Nordisk for zaltenibart.

Novo Nordisk’s $4.7B Akero deal boosts its metabolic health pipeline, targeting Eli Lilly’s lead in obesity and liver disease treatments

Omeros stock jumps 164% as Novo Nordisk acquires global rights to zaltenibart, with potential milestones reaching $2.1 billion and tiered royalties.

The company is one of two major players in the rapidly growing obesity drug market. Yet, the stock has lost half its value.

Scholar Rock stock falls as FDA issues Form 483 to Catalent; company to meet FDA, while apitegromab shows lean mass preservation in trial.

Regeneron and Scholar Rock’s submissions have been delayed or denied following an FDA inspection at the third-party fill-finish facility Catalent Indiana, owned by Novo Nordisk.

The company is readying to take on pharma giants Novo Nordisk and Eli Lilly.

This beaten-down drugmaker is well positioned to turn things around.

Now may be the time to invest in drug companies, as they just slipped the tariff noose.